Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.20% | 11.75% | 12.62% | 9.84% | 8.81% |
| Total Other Revenue | 3.24% | 5.64% | -0.10% | -2.57% | 34.09% |
| Total Revenue | 8.67% | 11.20% | 11.59% | 8.84% | 10.69% |
| Cost of Revenue | 25.20% | 28.13% | 22.59% | 19.56% | -25.83% |
| Gross Profit | 7.33% | 9.84% | 10.54% | 7.82% | 15.25% |
| SG&A Expenses | -14.97% | -12.98% | -0.97% | -3.41% | 37.86% |
| Depreciation & Amortization | 5.60% | 8.07% | 35.36% | 31.92% | 51.58% |
| Other Operating Expenses | -- | -- | -2,218.75% | -2,185.19% | -- |
| Total Operating Expenses | 2.49% | 4.88% | 7.01% | 4.37% | 23.99% |
| Operating Income | 17.07% | 19.80% | 14.51% | 11.69% | -3.41% |
| Income Before Tax | 48.12% | 51.58% | 14.24% | 11.42% | 0.49% |
| Income Tax Expenses | 103.02% | 107.76% | -6.29% | -8.60% | 19.37% |
| Earnings from Continuing Operations | 28.69% | 31.70% | 26.80% | 23.67% | -4.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.69% | 31.70% | 26.80% | 23.67% | -4.84% |
| EBIT | 17.07% | 19.80% | 14.51% | 11.69% | -3.41% |
| EBITDA | 16.61% | 19.34% | 15.02% | 12.18% | -2.00% |
| EPS Basic | 27.40% | 30.29% | 25.02% | 21.90% | -5.15% |
| Normalized Basic EPS | 46.47% | 50.08% | 12.61% | 9.86% | 0.33% |
| EPS Diluted | 31.98% | 35.16% | 30.02% | 26.91% | -4.43% |
| Normalized Diluted EPS | 51.79% | 55.71% | 17.40% | 14.50% | 0.86% |
| Average Basic Shares Outstanding | 1.05% | 1.05% | 1.44% | 1.44% | 0.28% |
| Average Diluted Shares Outstanding | -2.55% | -2.55% | -2.70% | -2.70% | -0.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.21% | -0.21% | -- | -- | 0.30% |